We demonstrate that an antibody that selectively detects a validated CDK5 phosphorylation site on the substrate CRMP2 robustly stains NSCLC, B-cell lymphoma and to a lesser extent breast carcinoma. The gene discussed is CDK5; the disease is B-cell non-Hodgkin lymphoma.